NMN Side Effects: What Studies Report

Nicotinamide mononucleotide (NMN) is a nicotinamide-based precursor within the nicotinamide adenine dinucleotide (NAD⁺) salvage pathway, and it has been studied as an oral compound intended to raise NAD⁺-related metabolites. A 2025 review summarised the biological properties, synthetic routes and proposed anti-aging mechanisms of NMN and reported that long-term safety characterisation and regulatory clarity remained among the principal outstanding challenges in the field (PMID 40550930). This page collects what the published safety and tolerability literature states, in the words of the studies themselves. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning supplements, medications or health conditions.

Human Tolerability: What Studies Report

Most of the available human safety information comes from randomised, placebo-controlled trials in healthy adults that lasted from a few weeks to a few months. A 2023 update that reviewed the human clinical trial literature on NMN reported that the trials published to that point described oral NMN as safe and well tolerated, with no serious treatment-related adverse events identified across the studies surveyed (PMID 37619764).

A randomised, multicentre, double-blind, placebo-controlled, parallel-group, dose-dependent trial in healthy middle-aged adults examined NMN at 300, 600 and 900 mg per day for 60 days, and researchers reported that supplementation was well tolerated at each dose level examined (PMID 36482258). The same trial reported dose-related increases in blood NAD⁺ concentrations, which the investigators used as the biological marker of exposure rather than as a clinical outcome (PMID 36482258).

A dedicated safety evaluation of oral β-NMN in healthy adult men and women administered 1250 mg per day for four weeks and the study reported that this regimen was considered safe, with no clinically meaningful safety findings among the parameters monitored (PMID 36002548). That publication is one of the few in which safety, rather than an efficacy endpoint, was the stated primary purpose of the trial.

Two longer trials in healthy, middle-aged Japanese men examined extended daily supplementation. One assessed metabolism, sleep parameters and NAD⁺ biosynthesis and reported that long-term NMN supplementation was tolerated without safety concerns emerging from the measures collected (PMID 38191197). A separate randomised, double-blind, placebo-controlled trial reported that long-term NMN supplementation altered NAD⁺-related metabolism while the measure of arterial stiffness did not differ meaningfully from placebo (PMID 36797393).

Which adverse events were actually named

An important nuance for anyone reading this literature is that the published abstracts of the principal human trials did not attribute specific severe adverse events to NMN. Instead, investigators reported an absence of serious treatment-related events and characterised the compound as well tolerated over the study periods (PMID 37619764, PMID 36482258). Absence of a reported signal in short trials with modest sample sizes is not the same as demonstrated absence of risk, a distinction the reviews themselves emphasise (PMID 35499054).

Laboratory and physiological monitoring

Safety assessment in these trials generally relied on routine clinical measurements rather than symptom diaries alone. The safety evaluation in healthy adults reported that haematology, blood chemistry and related clinical parameters were monitored and did not indicate safety problems attributable to the administered NMN (PMID 36002548). The 2023 review of human trials similarly reported that the studies it surveyed used clinical and laboratory monitoring and did not identify serious abnormalities linked to supplementation (PMID 37619764).

Doses and Durations Examined in Published Trials

The table reproduces regimens as described by the investigators. It is a record of what was studied, not a guide to use, and the doses listed are specific to the populations and durations in each protocol.

Preclinical Toxicology: What Studies Report

Before most of the human work, formal toxicology testing was published for at least one commercial NMN preparation. That safety evaluation reported results from genotoxicity assays and repeated-dose oral toxicity testing in rats, and researchers reported no genotoxic activity in the assays performed and no adverse effects at the highest dose examined, from which a no-observed-adverse-effect level was derived (PMID 34867355). Animal toxicology of this kind is designed to screen for organ toxicity, mutagenicity and gross physiological disturbance; it does not predict subjective complaints in people, nor interactions with medications.

Context From Mechanistic and Disease-Model Research

A substantial share of the NMN literature is mechanistic animal work rather than human safety assessment, and those studies are sometimes misread as safety evidence. In aged female mice, one study reported that NAD⁺ repletion with an NMN-based approach improved oocyte quality and measures of fertility during reproductive aging (PMID 32049001). Separate work on early pregnancy reported that NAD⁺ metabolism contributed to the homeostasis of decidual macrophages in a model system (PMID 40471104). Neither publication constitutes human safety data for use during pregnancy or fertility treatment.

Disease models also show that NAD⁺ handling is context-dependent rather than uniformly beneficial. One 2025 study reported that SARM1, an enzyme that consumes NAD⁺, exacerbated pressure overload-induced cardiac hypertrophy and heart failure by enhancing NAD⁺ metabolism in the model used (PMID 40662942). Findings like that illustrate why reviewers treat pathway-level extrapolation cautiously.

Multi-ingredient formulations complicate attribution

NMN is often studied alongside other compounds, which makes single-ingredient attribution of any effect or complaint difficult. One study examined the acute response to different NAD⁺ precursors included in combined metabolic activator formulations and reported differences in the resulting plasma metabolite profiles between precursors (PMID 37271226). When a formulation contains several actives, tolerability observations belong to the formulation as tested, not to NMN alone.

Safety Questions the Reviews Still Describe as Open

Review articles have been consistently more cautious than individual trial abstracts. A 2022 review of NMN as an anti-aging health product examined both the claimed benefits and the safety concerns, and reported that the human evidence base consisted largely of short-duration studies, leaving longer-term safety insufficiently characterised (PMID 35499054). The 2025 review reached a comparable conclusion, reporting that mechanistic promise was accompanied by unresolved questions about long-term use, product characterisation and regulatory standing (PMID 40550930).

Recurring limitations named in this literature include:

• Short exposure windows. The safety-focused human study reported four weeks of administration, and the dose-ranging trial reported 60 days (PMID 36002548, PMID 36482258), which cannot address multi-year use.
• Narrow populations. Trials have concentrated on healthy middle-aged adults, including single-sex cohorts of middle-aged Japanese men (PMID 38191197).
• Surrogate endpoints. NAD⁺ and related metabolites were commonly the primary measured outcome rather than clinical events (PMID 36797393).
• Unresolved long-term risk characterisation, as stated directly in the review literature (PMID 35499054, PMID 40550930).

What the Published Safety Literature Does Not Cover

Several categories remain outside the scope of the verified human trials above. Published NMN trials in the sources summarised here did not report safety outcomes in pregnancy or lactation, in children or adolescents, in people with significant kidney or liver disease, or in people taking multiple prescription medications. The pregnancy-related and fertility-related NAD⁺ work available is preclinical (PMID 32049001, PMID 40471104). Drug–supplement interaction studies were also not part of the trial reports summarised here, and the 2023 update of human trials framed its conclusions around the healthy adult populations that had been studied (PMID 37619764).

How to Read a Tolerability Statement

When a trial reports that a compound was "well tolerated", that phrase describes the events recorded during a specified protocol at specified doses in a specified group, verified against monitoring schedules the investigators chose. It is not a statement about a different dose, a longer duration, a different formulation or a different person. Readers comparing publications will find it useful to note four things for every study: who was enrolled, what regimen the study administered, how long the exposure lasted, and which safety measures were actually collected. The trials cited on this page differ on all four dimensions, which is why the reviews describe the overall safety picture as encouraging in the short term yet incomplete (PMID 37619764, PMID 35499054).

Nothing on this page is a recommendation, and no regimen described here should be interpreted as guidance. Regulatory classification of NMN products has also been a recurring topic in the review literature, which reported that regulatory status and product standardisation were unsettled alongside the scientific questions (PMID 40550930). Again: this page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision about a supplement or medication.

References

• The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update (Advances in Nutrition, 2023)
• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (GeroScience, 2023)
• Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women (Scientific Reports, 2022)
• Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men (Endocrine Journal, 2024)
• Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial (Scientific Reports, 2023)
• Safety Evaluation for Restorin® NMN, a NAD+ Precursor (Frontiers in Pharmacology, 2021)
• Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns (Journal of Advanced Research, 2022)
• Biological properties, synthetic pathways and anti-aging mechanisms of nicotinamide mononucleotide (NMN): Research progress and challenges (Biogerontology, 2025)
• The acute effect of different NAD+ precursors included in the combined metabolic activators (Free Radical Biology & Medicine, 2023)
• NAD+ Repletion Rescues Female Fertility during Reproductive Aging (Cell Reports, 2020)
• NAD+ Metabolism Maintains the Homeostasis of Decidual Macrophages in Early Pregnancy (FASEB Journal, 2025)
• SARM1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure by Enhancing NAD+ Metabolism (FASEB Journal, 2025)